IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The study objective was to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over
placebo by evaluation of treatment success analyzing the investigator's rating on the Facial
Wrinkle Scale and the patient's assessment on a 4-point scale. 255 female and male patients
with moderate to severe glabellar frown lines to be randomized in a 2:1 ratio to receive one
injection of IncobotulinumtoxinA (Xeomin) or placebo and will be followed up until day 120.
Phase:
Phase 3
Details
Lead Sponsor:
Merz Pharmaceuticals GmbH
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA